Painful diabetic neuropathy has always been a challenging complication of diabetes mellitus. Emerging theories suggest that early dysaesthesia associated with painful neuropathy may act as a marker for the development of the 'at risk' foot, allowing preventative clinical strategies to be undertaken. The mechanisms of neuropathic pain are complex. The authors' intentions are to help members of the diabetes care team better understand and appreciate the diverse symptoms reported by patients. The various treatments available for painful neuropathy are discussed in detail. Robust comparative studies on such treatments are, however, unavailable and the authors have designed a logical approach to management based on best current evidence and their own clinical experience.
Introduction
Diabetes mellitus is one of the most common chronic medical conditions affecting over 100 million people world-wide [1, 2] , of whom up to 60% may develop diabetic polyneuropathy [3 -6] . Its incidence is linked to the duration of diabetes [7, 8] . Studies by Veves et al. [9] and Galer et al. [2] have reported that among diabetic neuropathic patients within the UK, between 43% and 53% experienced painful symptoms to the lower limb. The rising prevalence of Type 2 diabetes is likely to increase the burden of this complication [10] .
The pathogenesis and subsequent successful treatment of established diabetic neuropathy are a challenging task for diabetes physicians [11] . This has been discussed since 1887, when Pavy documented his proposed hyperalgesic form of neuropathy, as cited by Archer [12] . The process of neuropathic pain generation is different from normal homeostatic physiological mechanisms. Our understanding of pain production has been underpinned by the 'alarm bell' principle, i.e. pain being the body's response to a perceived or received noxious stimulus, its role being largely protective [13, 14] . However, neuropathic pain often presents as a chronic and /or persistent pain, offering no overt biological cause, yet invoking both physical and emotional pain responses [15] . Although the pathogenesis has yet to be fully explained, there is an emerging consensus that persistent neuropathic pain results from damage to and subsequent morphological adaptive repair of either the central and /or peripheral nervous system ('neuroplasticity') [16] [17] [18] .
Methodology
A systematic review of MEDLINE, Embase, ISI (Web of Science) and Cinahl databases was undertaken. An initial search strategy was adopted sensitive to subject headings and abstracts displaying articles relating to painful neuropathy. Refinement of these search criteria was subsequently undertaken to reflect studies specifically related to painful diabetic peripheral neuropathy. However, relevant material from the initial search was retained.
Normal mechanisms of pain perception
Pain is the body's endogenous warning of actual or potential tissue damage. The primary pain receptors (nociceptors) are bare sensory nerve endings, which terminate in tissues and organs throughout the body and react to noxious stimuli. Pain transmission is via the axons which manifest as either small myelinated (A delta) or thinner unmyelinated (C) fibres, each performing specific tasks. Somatic pain arises from the skin, muscles or joints and can be classed as either superficial or deep. Superficial pain is often a sharp or pricking sensation and is transmitted along the fine lightly myelinated A delta fibres. Alternatively, deep somatic pain, often a burning, itching or aching type of pain with longer duration, arises from the deeper layers of soft tissue or joint. In normal conditions, this form of pain almost always indicates tissue damage and is conducted along the slower unmyelinated C fibres.
Following tissue damage, release of inflammatory chemicals, such as histamine and prostaglandins, is triggered, sensitizing the nociceptors. This is augmented by one of the most potent nociceptor activating substances, bradykinin. As superficial and deep somatic pain fibres (primary afferent neurones) enter the spinal cord and synapse in the dorsal horn with second-order neurones, substance P is released into the synaptic cleft. In the main, second-order neurones traverse the spinal cord and ascend in the anterolateral spinothalamic tracts, affecting synapse in the thalamus with subsequent relay to the somatosensory cortex for interpretation.
Pathogenesis
There are many clinical classifications of diabetic neuropathy; the authors' aim is to review the proposed pathogenic theories surrounding diabetic sensorimotor neuropathic pain. Limited study into early stage demyelination has largely failed to outline a suitably robust predictive model, as initial degradation appears to have minimal effect on nerve conduction velocity [19] . Investigations by Holland [20] and Levy [21] have reported that afferent (sensory) and efferent (motor) nerve fibre types may not be uniformly affected, partly explaining the wide range of symptoms associated with painful neuropathy. The various definitions for the more common types of pain are shown in Table 1 .
Proposed alterations in pain transmission

Gating theory
This theory was first proposed by Melzack and Wall in 1965 and described a pain 'gate' mechanism located within the dorsal horn of the spinal cord, where impulses from small unmyelinated C fibres and larger myelinated A β fibres enter the cord [13] . In principle, if electrical impulses from C fibres (pain transmission) outnumber those transmitted along the A β fibres (light touch /pressure transmission), the 'gate' opens and pain impulses are transmitted. Similarly, if the reverse is true, the gate is closed by enkephalin-releasing interneurones, leading to the inhibition of pain impulses [17] . A classic example is the rubbing of an injured site immediately after suffering trauma, resulting in gate closure.
However, certain features of the diabetic state seem to play an important role in the maintenance of this homeostatic process [22] . Miki et al . [23] have shown in animal models that myelinated A β fibres actively switch to the synthesis of substance P following injury. Substance P is a 'neuromodulator' that strengthens the pain signal [24] . Consequently, peripheral low threshold stimuli (light touch) would be sufficient to make Melzack and Wall's 'gate' resemble a revolving door to pain transmission.
Spinal rewiring
A-fibre sprouting has been previously reported in diabetic peripheral nerve damage [24 -26] . A fibres occur in all laminae of the dorsal horn, except the superficial lamina II [26] [27] [28] . This area is normally innervated by nociceptor C fibres exclusively, although injury seems to stimulate 'rewiring' (Fig. 1 ) [28] . Approximately 2 weeks following nerve injury, substance P, normally found only in C fibres, is released by larger diameter A fibres in the dorsal column nuclei [15] . As a result, central nervous system (CNS) pathways normally responsible for nociceptor information transmission are replaced by sprouting A fibres conveying non-noxious information, but releasing substance P. Such information is interpreted as mechanical allodynia and may account for the phenomenon of 'phantom limb' pain [29] .
Although observed in some cases of asymptomatic neuropathy, 'spinal rewiring' probably contributes to the pathogenesis of painful neuropathy [24, 30] .
Central spinal sensitization
Persistent nerve stimulation leads to activation of N-methyl-Daspartate (NMDA) receptors located on the post-synaptic membrane in the dorsal horn of the spinal cord [31] . The NMDA complex is both a voltage and ligand sensitive receptor. It has an ion channel, which is blocked by a magnesium (Mg ++ ) ion during its resting membrane potential [32] . Subsequent glutamate (an excitatory neurotransmitter) release and binding causes extended depolarization with an influx of calcium and sodium and efflux of potassium. As a result, subsequent stimuli produce much larger post-synaptic potentials than usual (synaptic potentiation) [17, 33] . The inhibitory effect of magnesium on the NMDA receptors partially explains its previous role in the treatment of epilepsy.
Long-term exposure to synaptic potentiation, as can be seen in painful peripheral diabetic neuropathy, may also persist due to an evolved state. Activated NMDA receptors appear to forge and enhance rapid links to the hippocampus, which is involved in memory and learning processes [34] . Consequently, alteration to NMDA receptors appears to cause an 'on fire' state and may give rise to the phenomenon of 'spinal windup' [35] . This can be defined as a continuous increased excitability of central neuronal membranes with persistent potentiation (Fig. 2) [13] .
Ectopic electrical impulses
Alteration to damaged axons causes sodium channels to accumulate, both at the injury site and along the entire length of the axon, favouring generation of ectopic electrical impulses and hyperexcitability [36] . In diabetic rat models, nociceptive fibres originating in the dorsal root ganglion fire in an exaggerated, spontaneous fashion [37] . It has been suggested by Boulton et al . [24] that the proximal activity of this focus, coupled with the damaged distal segment of the axon, leads to the clinically painful, yet insensate leg. This finding supports a varied aetiology for the mechanisms of neuropathic pain.
Howe et al . [38] and Wall et al . [39] have also shown that thresholds to thermal, mechanical and chemical stimuli are reduced following spontaneous electrical activity. Neighbouring uninjured axons also display spontaneous discharge activity [40, 41] . As a result, electrical impulse bursts to the dorsal horn are increased, leading to alterations in 'gating' and substance P, with subsequent pain mediation as described earlier.
The association between ectopic discharge and increased sodium channels explains the therapeutic role for membrane stabilizers such as anti-convulsants and tricyclic antidepressants in the treatment of neuropathic pain. 
Metabolic control
Rapid changes in glycaemic control have often been implicated as a trigger for diabetic neuropathic pain [42] . It is still uncertain whether elevated glucose levels, or indeed, fluctuations in blood glucose, are related to painful symptoms [43, 44] . Nevertheless, there is a growing interest in the role of rapid, tight glycaemic control. A study by Boulton [45] using continuous subcutaneous insulin infusion demonstrated an amelioration of painful diabetic neuropathic symptoms and improved motor conduction velocity. Furthermore, the Diabetes Control and Complications Trial has shown that intensive glycaemic control reduces the prevalence and progression of peripheral neuropathy. Morphological investigation by Perkins [46] also suggests that the severity of distal diabetic sensorimotor polyneuropathy, as expressed by fibre density, is significantly related to glycaemic control in both Type 1 and Type 2 diabetic individuals. Sudden improved glycaemic control in patients started on insulin treatment may cause a type of 'painful neuritis' [47] .
Other metabolic factors include the polyol pathway leading to nerve sorbitol accumulation, myoinositol reduction and structural nerve damage [48, 49] . More recently, Tesfaye et al . [50] have implicated severe epineurial vessel structural disease including arterio-venous shunting. Tesfaye et al . [50] have also demonstrated endoneurial hypoxia resulting from arteriovenous shunting with the proliferation of new leaky neural vessels. Support for an endoneurial 'steal effect' also comes from previous studies, which have shown increased skin temperature and blood flow in diabetic neuropathic pain [51, 52] .
Pharmacological therapies
There are currently no available treatments which restore nerve function. Management relies mainly on the pharmacological treatment of overt symptoms, namely severe pain. Overthe-counter analgesics may provide short-term pain relief, but long-term treatment normally requires the prescription of systemic or topical pharmacological agents.
Antidepressants Tricyclic antidepressants
Since the 1970s, tricyclic antidepressants (TCAs) have represented the first-line treatment for painful diabetic peripheral neuropathy [53] . Studies have shown that these agents promote successful analgesia to thermal, mechanical and electrical stimuli in diabetic patients [54, 55] . They may have, however, intolerable side-effects related mainly to their anti-cholinergic action [56] . These include sedation, blurred vision, dry mouth, orthostatic hypotension and cardiac arrhythmias. Of patients prescribed TCAs for the management of pain, 7-58% report either ineffective pain relief or side-effects precluding optimal dosage [57] . However, Sindrup et al . [58, 59] have demonstrated the success of optimal plasma concentrations of the active drug and metabolite.
Collins et al . [53] suggest that TCAs be prescribed for burning pain symptoms, although there is no direct association between this particular pain manifestation and drug efficacy. Moreover, extensive reviews by McQuay et al. [55, 60] have questioned a role for TCAs as a first-line treatment. Although current trends favour TCAs such as trimipramine and amitryptyline [61] , an effective response may be delayed for 2-3 weeks after initiating treatment. The effective therapeutic dose required has been shown to differ between patients, and a gradually incremented dose according to response is suggested.
TCAs inhibit re-uptake of noradrenaline and serotonin [34] . They also seem to alter the mode of action of α 1 adrenergic receptors, reducing sympathetic activity and blocking hyperalgesia induced by NMDA receptors (spinal wind-up theory) [62] . Unfortunately, whilst most studies report an improvement in perceived pain levels, specific information relating to thermal and mechanical modalities is currently unavailable.
Selective serotonin re-uptake inhibitors
This subclass of antidepressant displays specificity for the presynaptic re-uptake of serotonin, thus reducing the side-effects frequently associated with TCAs [63] . Their mode of action is based around experimental observations that serotonin is an important mediator of analgesia [64] . Despite these potential advantages, the results from three trials [57, 59, 65] have been particularly disappointing. There is, however, some evidence that paroxetine reduces lancinating pain [66] .
Anti-convulsants Gabapentin
Gabapentin has been used since 1994 for the management of partial epilepsy and is the only drug of its type licensed for treatment of neuropathic pain in the UK [67] . Structurally, it is an analogue of γ -aminobutyric acid (GABA), which plays a role in pain transmission and modulation [56] . Pharmacologically, it appears to have no direct effect on GABA uptake or metabolism. Gabapentin seems to inhibit voltage-activated calcium and sodium channels, suggesting an analgesic affect at spinal cord level [68] . It has also been shown to be effective in heat hyperalgesia and mechanoallodynia in CCI rat models [69, 70] .
Two large placebo-controlled, parallel design trials by Backonja [56] and Rowbotham [71] have shown significant pain relief with gabapentin at a dose of 1800 mg /day. Both studies monitored global pain relief and quality of life scores, showing objective improvement in both modalities. A small scale study [72] comparing gabapentin and amitriptyline showed no significant difference in efficacy, although patients on amitriptyline had significant weight gain and more side-effects.
Gabapentin is generally well tolerated and seems to be most effective at doses of 1800 mg daily or above [56] . Mellegers' [73] systematic review of gabapentin for neuropathic pain has highlighted the variability of study dose regimes, suggesting that very low doses have limited effect. Rapid titration appears to increase the incidence of central nervous system side-effects. Whilst there is no need for blood monitoring, some patients may experience minor side-effects such as dizziness, somnolence, headache, diarrhoea, confusion and nausea [71] .
Carbamazepine
Carbamazepine has been shown in animal models to reduce pain induced by inflammatory mediators [74] . It also displays inhibitory properties in CCI rat models, suggesting suppression of spontaneous ectopic activity [75] . Nevertheless, its use in painful diabetic neuropathy is limited. Two small randomized, placebo-controlled studies by Rull et al . ( n = 13) and Wilton ( n = 40), cited by Tremont [25] and McQuay [60] , showed a marginally superior analgesic effect with carbamazepine. Another study by Gomez-Perez [76] comparing analgesic effects of carbamazepine, nortriptyline and fluphenazine showed no significant difference between these drugs.
Phenytoin
The role of phenytoin in pain management is based on work by Bergouignan in 1942. Recent placebo-controlled studies on diabetic neuropathy reveal inconsistent findings [53] . Saudek et al . [77] report no significant difference between phenytoin and placebo, whereas Chadda et al . [78] observed some beneficial effect at high dose (600 mg /day). As expected, adverse effects such as giddiness were common in both these studies, affecting 10% of participants.
Lamotrigine
This drug represents another new development of anticonvulsant sodium channel and presynaptic glutamate blocking therapy, which may possess beneficial properties for pain relief. At present, only two studies have assessed its efficacy in human diabetic neuropathic pain, both conducted by Eisenberg [79, 80] . The initial trial involved an open label design with relatively small numbers ( n = 15), concluding that lamotrigine may reduce painful diabetic neuropathy. A subsequent trial was randomized, double-blinded, placebo-controlled and reported a significant reduction in pain intensity over placebo at a daily dose of 200 -400 mg. Primary and secondary outcome measures adopted were a numerical pain scale, McGill Pain Questionnaire (MPQ) and Beck Depression Inventory (BDI). However, the sample size remained small ( n = 59) and the sensitivity of the BDI to detect potential mood alteration caused by the drug was largely ineffective due to the relatively short duration (3 weeks at optimal dose). Larger studies with longitudinal designs are needed.
Topiramate
Topiramate is a new generation anti-convulsant. It has multiple mechanisms of action, displaying an ability to block sodium channels and potentiate GABA activity by interacting with GABA A receptors [81] . A double-blind, placebo-controlled trial by Edwards et al . [82] has reported a significant reduction in the Visual Analogue and Short Form McGill Pain Questionnaire scores. However, the withdrawal rate for participants on topiramate was 28%, confusion being a common adverse effect. Its precise role remains uncertain.
Pregabalin
Pregabalin is a GABA analogue with apparently no effect on GABA receptors [17] . Current evidence also suggests no direct interaction with sodium or calcium channels, and its mechanism is unknown [25] . One abstract of a randomized, controlled study relating to this drug is currently available, showing a positive improvement in pain, sleep and global impression of change scores [83] . Further multicentre trials are currently planned.
Anti-arrhythmic agents Lignocaine
The potential beneficial use of lidocaine in diabetic painful neuropathy was first reported by Kastrup [84] . A further randomized, double-blind, crossover trial conducted by Petersen [85] recorded a significant beneficial effect of lidocaine infusion (5 mg /kg over 30 min) compared with a saline infusion. However, outcome measurement (clinical symptom scale) was terminated on the eighth day, thus the potential length of pain relief could not be fully assessed. Lignocaine is often reserved for patients exhibiting excruciating neuropathic pain and is not appropriate for long-term treatment. This is because oral dosing is unavailable and electrocardiogram (ECG) monitoring is required during intravenous (i.v.) administration [86] . It has, however, been shown to be effective in other pain-related states, such as trigeminal and post-herpetic neuralgia [87, 88] .
Mexiletine
Mexiletine is an oral analogue of lignocaine but is rarely used in the management of diabetic neuropathic pain [89] . Four studies reported a variable analgesic effect (dose range 225-675 mg /daily). Two [90, 91] reported a superior effect of mexiletine over placebo. In contrast, others [92, 93] show no pain reduction, when compared with placebo.
Topical treatments Capsaicin
Capsaicin is a natural colloid extracted from red chilli peppers, which depletes substance P from afferent nerves [94] . Its topical application has displayed promising effects on diabetic neuropathic pain in three parallel studies [95] [96] [97] . A doubleblind study comparing capsaicin and oral amitriptyline [98] showed no significant difference in pain relief between the two groups, but more serious side-effects were experienced in patients on amitriptyline.
Although capsaicin has few serious side-effects, it frequently causes burning, tingling, erythema and stinging at its application site. In addition, whilst there is often some pain relief after 2 weeks, a maximum therapeutic effect may be delayed for up to 4-6 weeks [99] . Co-operation with treatment is also made more difficult by the need for application three to four times a day (0.075%).
Op-site
Op-site film dressings have been shown to relieve pain on open wounds [100] . However, its use in the treatment of diabetic pain is largely anecdotal. A randomized controlled study by Foster [101] did reveal significant pain reduction using Visual Analogue Pain Scales and quality of life data (mobility, sleep, etc.). Op-site seems to act as a barrier to exogenous stimuli and may be useful in relieving allodynia.
NMDA antagonists Dextromethorphan
The role of excitatory amino acids in neuropathic pain has lead to the use of dextromethorphan, a low affinity NMDA receptor blocker, which shows promising results in relieving diabetic neuropathic pain [102] . Nelson et al . [103] reported significant pain improvement with dextromethorphan over placebo using a crossover design. However, the sample size in this study was small ( n = 13).
Narcotic analgesics
There are few published data involving opiates in painful diabetic neuropathy. However, two key studies by Harati [104, 105] have evaluated tramadol in a 6-month open extension following the findings of a preliminary 6-week doubleblind randomized trial. The results at 6 weeks suggested that 210 mg /day split doses were significantly better in reducing pain compared with placebo, in both physical and social functioning scores. The extension [105] incorporated the majority of participants from the first phase ( n = 117). Selfadministered pain intensity and pain relief ratings concluded that tramadol was able to provide long-term reduction in pain relief. However, a total of 17 patients were unable to complete the trial due to either ineffective pain relief ( n = 4) or adverse events ( n = 13). This represents a 14.5% attrition.
Anecdotally, specialists tend to prescribe mild or strong oral opiates as an adjunct to treatment in severely painful neuropathy. The range of opiates prescribed includes codeine, tramadol, oxycodone and methadone. Studies on the effect of narcotics on pain remain limited to post-herpetic neuralgia [106] . Sedation, of course, is a common side-effect with opiates, as is constipation, nausea and vomiting. Possible dependency is also a problem related to long-term usage, and patients need to be reviewed regularly to monitor pain and record drug utilization [107] .
Non-steroidal anti-inflammatory drugs
Only one available study [108] shows a role for non-steroidal anti-inflammatory drugs as effective analgesics for diabetic neuropathic pain. Outcome measurements were, however, not made available and the validity of these findings is uncertain.
Neurokinin receptor antagonists Lanepitant
Substance P is thought to mediate pain and inflammation through binding to the neurokinin 1 receptor (NK-1) [109] . Lanepitant is a potent selective NK-1 antagonist, the effects of which have been found to be successful in animal models of persistent pain [110] . However, there is little evidence for its role in human painful diabetic neuropathy. Although lanepitant is an ineffective monotherapy, it may have a role as an adjunct therapy with NMDA antagonists [111] .
Non-pharmacological therapies Nerve stimulation therapies
Nerve stimulation therapies include transcutaneous electrical nerve stimulation (TENS), percutaneous electrical nerve stimulation (PENS) and acupuncture. Their mode of action is thought to be related to stimulation of endogenous opioids at spinal cord level, invoking the 'gating' principle [99, 112, 113] . The main advantage of the TENS system is its portable nature as a topical application of low-frequency currents, making it safe. TENS machines are clearly contraindicated in patients with pacemakers.
A trial conducted by Meyler [114] evaluated the use of TENS in 200 patients with a variety of pain syndromes. The results demonstrated that 53% with peripheral nerve damage reported pain reduction. However, not all patients had painful diabetic neuropathy. In the absence of a sham TENS arm, placebo bias may have been present.
A review by Alvero [115] evaluated three key studies [116] [117] [118] on painful diabetic peripheral neuropathy. One demonstrated a 52% improvement in pain perception within 2-3 weeks of starting TENS [116] . Kumar et al . [117] displayed a 26% amelioration of pain perception in diabetic patients treated with amitriptyline alone. The trial also investigated amitriptyline and TENS treatments as combination therapy. Analogue scales were recorded after a 4-week period and illustrated a 66% reduction in pain levels. A third study by Alvero examined the long-term effectiveness of TENS [118] . There was a 44% improvement in pain, assessed by detailed self-administered questionnaire. Data from these studies appear promising, but the sample sizes were small ( n = 31, n = 26, n = 54, respectively).
Acupuncture requires the specialist application of fine needles into the skin to relieve pain and is generally well tolerated. Abuaisha [119] evaluated its efficacy and long-term effectiveness in 46 diabetic individuals with chronic painful peripheral neuropathy. Outcome was assessed with a visual analogue scale, with 34 displaying significant improvement. Over 18-52 weeks, 67% of the patients stopped or reduced their medications. These limited data suggest that acupuncture is safe and potentially effective [119, 120] . An important limitation is the lack of trained therapists in this field, reducing its overall availability and scope for further research.
PENS is an electroanalgesic therapy incorporating both TENS and acupuncture [121] . Studies by Tesfaye [122] and Ahmed [123] using this modality have reported short-term relief in various acute and chronic pain syndromes. A randomized, controlled, crossover study by Hamza [121] over 3 weeks has also reported a significant improvement in both visual analogue and sleep scores. The Beck Depression Inventory and the Profile of Mood States at baseline and after completion of each modality suggested greater improvement in actively treated patients. PENS may also be useful when treating diabetic neuropathic pain.
Electrical spinal-cord stimulation
The use of electrical spinal cord stimulation is a radical treatment for certain patients with chronic neuropathic pain. An electrode is implanted into a thoracic / lumbar disc space, and this seems to stimulate endogenous opiate production in a similar manner to TENS [113] . Tesfaye et al. have examined this technique in 10 diabetic patients with chronic neuropathic pain over a 14-month period [122] . They showed a significant reduction in pain in eight, at 3 and 14 months. As this procedure is invasive, it should be reserved for patients with pain refractory to more conventional treatments
Counselling and psychological treatments
The objective of this approach is to train patients to recognize the influence of thought and perception over pain responses [124] . The patient is taught techniques to exert control over physiological processes such as muscle tension and relaxation. However, its success depends on the commitment of the patient, and expert opinion suggests limited rates of patient compliance. Moreover, the staffing required often falls outside the resources of a diabetes clinic.
Selection of treatment for painful diabetic neuropathy
As comparative efficacy studies on the available treatments are unavailable, the authors have designed a care pathway (Fig. 3) based on their own experience with licensed available preparations in the UK. In a patient with newly diagnosed painful diabetic neuropathy, which is severe enough to disturb sleep, TCAs would be our first choice of treatment, as these agents restore sleep adequately [54] . Amitryptiline is a commonly prescribed agent, but less sedating TCAs such as imipramine or nortryptiline may be preferable for some patients. The usual starting dosage is 10 mg at night, increasing the dose as necessary to a maximum of 100-150 mg daily. The slow onset of action of TCAs and their potential side-effects often require a gradual dose build-up (3-4 weeks) before maximum efficacy and tolerance are achieved. Gabapentin is our recommended alternative treatment in patients with persistent symptoms, possibly in combination with a small dose of TCA (10-25 mg) in those with sleep disturbance.
Topical treatments such as capsaicin or Op-site may also be appropriate first-choice agents in some patients, particularly those with milder symptoms or those with more severe symptoms but who have difficulty taking tablets. Such treatments may also be desirable for patients who become intolerant of TCAs (e.g. dry mouth, excessive daytime sedation) or in whom TCAs are contraindicated (e.g. significant ischaemic heart disease).
In patients with more acute pain, the authors recommend gabapentin as a first choice of treatment, as this may be titrated to the recommended maintenance dose (600 mg t.i.d.) over 3-5 days, much more quickly than TCAs [68] .
For patients who experience intermittent severe breakthrough pain, an opiate analgesic such as codeine (30-60 mg) may be appropriate. Such treatments should be reserved for patients who understand the risk of possible dependency related to long-term usage. Patients should be told to avoid regular dosing, and they need to be reviewed regularly to monitor pain and record drug utilization [107] .
Treatment may be considered successful in patients who experience a moderate decrease in pain or improved function. In practice, complete elimination of pain is rare, if not impossible with the available drugs. For this reason, patient education is a crucial part of management. Thus, the potential limitations of therapy should be highlighted, so that patients adopt realistic expectations from an early stage. The need for good glycaemic control, coupled with appropriate diet and lifestyle, is also vital in the prevention and management of painful neuropathy and should form a pivotal part of the education process. As a general rule, rapid changes in glycaemic control should be avoided in all diabetic patients. Hospital admission should be considered in patients whose symptoms are severe enough to lead to depression, poor self-care or relationship difficulties. Such patients may obtain temporary pain relief from i.v. lignocaine treatment as described earlier. Whilst in hospital, other longer term treatment options such as TENS may be considered. Some patients may also benefit from professional counselling or psychotherapy. Referral to a centre specializing in more invasive techniques such as spinal cord stimulation may be considered in extreme cases.
Continuity of patient care is essential in the management of painful neuropathy. Dedicated clinics with adequate followup enable appropriate follow-up once treatment is initiated. This facilitates alteration of drug dosages or medication in relation to patient feedback, and is likely to improve compliance. Some centres already report clear benefits following the adoption of specialist clinics [125] . Such clinics may further help to establish an early diagnosis of painful diabetic neuropathy and exclude other painful conditions of the lower extremity, such as musculoskeletal foot problems.
To the authors' knowledge, there are currently no published guidelines on the management of painful neuropathy. The suggested care pathway is intended to help the diabetes care team adopt a safe and logical approach to treatment.
